Source link : https://www.newshealth.biz/health-news/novel-therapy-reduced-liver-fat-improved-fibrosis-in-mash/
Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel small molecule thyroid hormone receptor agonist achieved statistically significant reductions in liver fat, the phase IIb randomized VOYAGE trial showed. At week 12, patients receiving VK2809 had significant reductions in liver fat, ranging from -49.5% with the 2.5-mg daily dose to -56.7% […]
Author : News Health
Publish date : 2024-11-21 15:27:56
Copyright for syndicated content belongs to the linked Source.